GLPwatch
Papers (10373)
Page 34 of 173, ranked by citation count.
- Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.
- Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet.
- Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice.
- As Semaglutide's Popularity Soars, Rare but Serious Adverse Effects Are Emerging.
- Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice.
- A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.
- Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist.
- Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide.
- Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States.
- Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).
- Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis.
- Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
- Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
- Drug-Induced Acute Pancreatitis: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database.
- Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
- Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial.
- Semaglutide Alleviates Ovary Inflammation via the AMPK/SIRT1/NF‑κB Signaling Pathway in Polycystic Ovary Syndrome Mice.
- Neurobehavioral effects of liraglutide and sitagliptin in experimental models.
- Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention.
- Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide.
- Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.
- Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease.
- The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.
- Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice.
- Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
- Alterations in energy balance following exenatide administration.
- Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys.
- Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets.
- Tirzepatide: A Review in Type 2 Diabetes.
- Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
- Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
- Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats.
- Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients.
- Dulaglutide Modulates the Development of Tissue-Infiltrating Th1/Th17 Cells and the Pathogenicity of Encephalitogenic Th1 Cells in the Central Nervous System.
- Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.
- Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.
- Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats.
- Exendin-4 enhances the differentiation of Wharton's jelly mesenchymal stem cells into insulin-producing cells through activation of various β-cell markers.
- Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
- Semaglutide in Adults with Type 1 Diabetes and Obesity.
- Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors.
- Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.
- Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study.
- Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice.
- Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.
- Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease.
- Pharmacologic Treatment of Obesity in Reproductive Aged Women.
- Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study.
- Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
- Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet.
- GLP-1-based therapies: the dilemma of uncertainty.
- LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.
- Liraglutide ameliorates renal injury in streptozotocin‑induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor‑κB pathway.
- Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats.
- Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.
- GLP-1 agonists inhibit ox-LDL uptake in macrophages by activating protein kinase A.
- Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction.
- MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.
- Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.
- Liraglutide alleviates H<sub>2</sub>O<sub>2</sub>-induced retinal ganglion cells injury by inhibiting autophagy through mitochondrial pathways.